-
1
-
-
0025645805
-
Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia
-
Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 1990;17 (3):241-246.
-
(1990)
Prostate
, vol.17
, Issue.3
, pp. 241-246
-
-
Guess, H.A.1
Arrighi, H.M.2
Metter, E.J.3
Fozard, J.L.4
-
2
-
-
0025296064
-
-
McNeal J. Pathology of benign prostatic hyperplasia: Insight into etiology
-
McNeal J. Pathology of benign prostatic hyperplasia: insight into etiology. Urol Clin North Am 1990;17:477-486.
-
(1990)
Urol Clin North Am
, vol.17
, pp. 477-486
-
-
-
3
-
-
0025370536
-
Androgen ablation and blockade in the treatment of benign prostatic hyperplasia
-
McConnell JD, George FW, Wilson JD, Geller J, Stoner E. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990;17:661-672.
-
(1990)
Urol Clin North Am
, vol.17
, pp. 661-672
-
-
McConnell, J.D.1
George, F.W.2
Wilson, J.D.3
Geller, J.4
Stoner, E.5
-
4
-
-
0037454386
-
Benign prostatic hyperplasia
-
Thorpe A. Benign prostatic hyperplasia. Lancet 2003;361 (9366):1359-1367.
-
(2003)
Lancet
, vol.361
, Issue.9366
, pp. 1359-1367
-
-
Thorpe, A.1
-
5
-
-
0036587079
-
The urologist view of BPH progression: Results of an international survey
-
Djavan B, Nickel JC, De la Rosette J, Abrams P. The urologist view of BPH progression: results of an international survey. Eur Urol 2002;41(5):490-496.
-
(2002)
Eur Urol
, vol.41
, Issue.5
, pp. 490-496
-
-
Djavan, B.1
Nickel, J.C.2
De La Rosette, J.3
Abrams, P.4
-
6
-
-
0032988661
-
Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK
-
Trueman P, Hood SC, Nayak USL, Mrazek MF. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK. BJU Int 1999;83(4):410-415.
-
(1999)
BJU Int
, vol.83
, Issue.4
, pp. 410-415
-
-
Trueman, P.1
Hood, S.C.2
Nayak, U.S.L.3
Mrazek, M.F.4
-
7
-
-
0026591918
-
The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association
-
Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549-1557.
-
(1992)
J Urol
, vol.148
, pp. 1549-1557
-
-
Barry, M.J.1
Fowler Jr., F.J.2
O'Leary, M.P.3
-
8
-
-
0029285148
-
Measuring disease-specific health status in men with benign prostatic hyperplasia
-
Measurement Committee of the American Urological Association
-
Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of the American Urological Association. Med Care. 1995;33:AS145-AS155.
-
(1995)
Med Care.
, vol.33
-
-
Barry, M.J.1
Fowler Jr., F.J.2
O'Leary, M.P.3
Bruskewitz, R.C.4
Holtgrewe, H.L.5
Mebust, W.K.6
-
9
-
-
84879580216
-
-
American Urological Association, updated 2006. Available at, (accessed June 13, 2012)
-
American Urological Association. AUA guideline on management of benign prostatic hyperplasia (2003/2006). Chapter 1: Diagnosis and treatment recommendations. 170:530-47; 2003; updated 2006. Available at: http://www.auanet.org/content/clinical-practice-guidelines/clinical-guidelines/ main-reports/bph-management/chap-1-GuidelineManagementof(BPH).pdf. (accessed June 13, 2012).
-
(2003)
AUA Guideline on Management of Benign Prostatic Hyperplasia (2003/2006) Chapter 1: Diagnosis and Treatment Recommendations
, vol.170
, pp. 530-547
-
-
-
10
-
-
58149229463
-
Watchful waiting in benign prostatic hyperplasia
-
Wiygul J, Babayan RK. Watchful waiting in benign prostatic hyperplasia. Curr Opin Urol 2009;19:3-6.
-
(2009)
Curr Opin Urol
, vol.19
, pp. 3-6
-
-
Wiygul, J.1
Babayan, R.K.2
-
11
-
-
0032991607
-
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
-
Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1-13.
-
(1999)
Eur Urol
, vol.36
, pp. 1-13
-
-
Djavan, B.1
Marberger, M.2
-
12
-
-
0033998198
-
Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia
-
the ALFORTI Study Group
-
van Kerrebroeck P, Jardin A, Laval KU, van Cangh P, the ALFORTI Study Group. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2000;37: 306-313.
-
(2000)
Eur Urol
, vol.37
, pp. 306-313
-
-
Van Kerrebroeck, P.1
Jardin, A.2
Laval, K.U.3
Van Cangh, P.4
-
13
-
-
67349102059
-
Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: Pooled results of 2 phase 3 studies
-
Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181:2634-2640.
-
(2009)
J Urol
, vol.181
, pp. 2634-2640
-
-
Marks, L.S.1
Gittelman, M.C.2
Hill, L.A.3
Volinn, W.4
Hoel, G.5
-
14
-
-
0032699893
-
Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: Analysis of a European, multinational, multicenter, openlabel study
-
European Tamsulosin Study Group
-
Schulman CC, Cortvriend J, Jonas U, et al. Tamsulosin: 3- year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, openlabel study. European Tamsulosin Study Group. Eur Urol 1999;36:609-620.
-
(1999)
Eur Urol
, vol.36
, pp. 609-620
-
-
Schulman, C.C.1
Cortvriend, J.2
Jonas, U.3
-
15
-
-
0031744756
-
Long-term effects of finasteride in patients with benign prostatic hyperplasia: A double-blind, placebo-controlled, multicenter study
-
PROWESS Study Group
-
Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998;51:677-686.
-
(1998)
Urology
, vol.51
, pp. 677-686
-
-
Marberger, M.J.1
-
16
-
-
38849201263
-
The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study
-
Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008;179:616-621.
-
(2008)
J Urol
, vol.179
, pp. 616-621
-
-
Roehrborn, C.G.1
Siami, P.2
Barkin, J.3
-
17
-
-
0347882750
-
The longterm effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
-
McConnell JD, Roehrborn CG, Bautista OM, et al. The longterm effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387-2398.
-
(2003)
N Engl J Med.
, vol.349
, Issue.25
, pp. 2387-2398
-
-
McConnell, J.D.1
Roehrborn, C.G.2
Bautista, O.M.3
-
18
-
-
74049146047
-
Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract
-
Fibbi B, Morelli A, Vignozzi L, et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 2010;7(1):59- 69.
-
(2010)
J Sex Med
, vol.7
, Issue.1
, pp. 59-69
-
-
Fibbi, B.1
Morelli, A.2
Vignozzi, L.3
-
19
-
-
79960159705
-
Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction
-
Uckert S, Oelke M. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol 2011;72(2):197-204.
-
(2011)
Br J Clin Pharmacol
, vol.72
, Issue.2
, pp. 197-204
-
-
Uckert, S.1
Oelke, M.2
-
20
-
-
56249104747
-
The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors
-
Kohler TS, McVary KT. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 2009;55(1):38-48.
-
(2009)
Eur Urol
, vol.55
, Issue.1
, pp. 38-48
-
-
Kohler, T.S.1
McVary, K.T.2
-
21
-
-
40649120162
-
Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue
-
Uckert S, Sormes M, Kedia G, et al. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 2008;71(3):526-530.
-
(2008)
Urology
, vol.71
, Issue.3
, pp. 526-530
-
-
Uckert, S.1
Sormes, M.2
Kedia, G.3
-
22
-
-
0031956895
-
Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor
-
Guh JH, Hwang TL, Ko FN, Chueh SC, Lai MK, Teng CM. Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol 1998;53(3):467-474.
-
(1998)
Mol Pharmacol
, vol.53
, Issue.3
, pp. 467-474
-
-
Guh, J.H.1
Hwang, T.L.2
Ko, F.N.3
Chueh, S.C.4
Lai, M.K.5
Teng, C.M.6
-
23
-
-
0032561332
-
Cell proliferation in human prostatic smooth muscle cells involves the modulation of protein kinase C isozymes
-
Guh JH, Chueh SC, Hwang TL, Chen J, Teng CM. Cell proliferation in human prostatic smooth muscle cells involves the modulation of protein kinase C isozymes. Eur J Pharmacol 1998;359(2-3):281-284.
-
(1998)
Eur J Pharmacol
, vol.359
, Issue.2-3
, pp. 281-284
-
-
Guh, J.H.1
Chueh, S.C.2
Hwang, T.L.3
Chen, J.4
Teng, C.M.5
-
24
-
-
34447134765
-
RhoA/Rho kinasemediated Ca2+ sensitization in the contraction of human prostate
-
Takahashi R, Nishimura J, Seki N, et al. RhoA/Rho kinasemediated Ca2+ sensitization in the contraction of human prostate. Neurourol Urodyn 2007;26(4):547-551.
-
(2007)
Neurourol Urodyn
, vol.26
, Issue.4
, pp. 547-551
-
-
Takahashi, R.1
Nishimura, J.2
Seki, N.3
-
25
-
-
62849084325
-
Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS
-
Coyne KS, Kaplan SA, Chapple CR, et al. . Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. BJU Int 2009;103:24-32.
-
(2009)
BJU Int
, vol.103
, pp. 24-32
-
-
Coyne, K.S.1
Kaplan, S.A.2
Chapple, C.R.3
-
26
-
-
12344288164
-
Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk
-
Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47:214-220.
-
(2005)
Eur Urol
, vol.47
, pp. 214-220
-
-
Rosano, G.M.1
Aversa, A.2
Vitale, C.3
Fabbri, A.4
Fini, M.5
Spera, G.6
-
27
-
-
79952749220
-
Tadalafil for the treatment if lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism (s) of action
-
Anderson KE, De Groat WC, McVary KT, et al. Tadalafil for the treatment if lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism (s) of action. Neurol Urodyn 2011;30:292-3011.
-
(2011)
Neurol Urodyn
, vol.30
, pp. 292-3011
-
-
Anderson, K.E.1
De Groat, W.C.2
McVary, K.T.3
-
28
-
-
10744221043
-
Lower urinary tract symptoms and male sexual dysfunction: The Multinational Survey of the Aging Male (MSAM-7)
-
Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 2003;44(6):637-649.
-
(2003)
Eur Urol
, vol.44
, Issue.6
, pp. 637-649
-
-
Rosen, R.1
Altwein, J.2
Boyle, P.3
-
29
-
-
60349128880
-
-
Cialis (tadalafil), Eli Lilly and Company: Indianapolis, IN: October
-
Cialis (tadalafil). Prescribing information. Eli Lilly and Company: Indianapolis, IN: October 2011.
-
(2011)
Prescribing Information
-
-
-
30
-
-
60349128880
-
-
Levitra (vardenafil), Bayer Health-Care Pharmaceuticals: Wayne, NJ: April
-
Levitra (vardenafil). Prescribing information. Bayer Health- Care Pharmaceuticals: Wayne, NJ: April 2011.
-
(2011)
Prescribing Information
-
-
-
31
-
-
60349128880
-
-
Viagra (sildenafil), Pfizer Labs: New York, NY: January
-
Viagra (sildenafil). Prescribing information. Pfizer Labs: New York, NY: January 2010.
-
(2010)
Prescribing Information
-
-
-
32
-
-
60349128880
-
-
Stendra (avanafil), Vivus, Inc: Mountain View, CA: April
-
Stendra (avanafil). Prescribing information. Vivus, Inc: Mountain View, CA: April 2012.
-
(2012)
Prescribing Information
-
-
-
33
-
-
69849087363
-
Is there a rationale for chronic use of phosphodiesterase inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
-
Roumeguere T, Zouaoui Boudjeltia K, Hauzer C, Schulman C, Vanhaeverbeek M, Wespes E. Is there a rationale for chronic use of phosphodiesterase inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? BJU Int 2009;104:511-517.
-
(2009)
BJU Int
, vol.104
, pp. 511-517
-
-
Roumeguere, T.1
Zouaoui Boudjeltia, K.2
Hauzer, C.3
Schulman, C.4
Vanhaeverbeek, M.5
Wespes, E.6
-
34
-
-
0035174618
-
Characterization and function relevance of cyclic nucleotide phosphodiesterase isoenzyme in the human prostate
-
Uckert S, Kuthe A, Jonas U, Stief CG. Characterization and function relevance of cyclic nucleotide phosphodiesterase isoenzyme in the human prostate. J Urol 2001;166: 2484-2490.
-
(2001)
J Urol
, vol.166
, pp. 2484-2490
-
-
Uckert, S.1
Kuthe, A.2
Jonas, U.3
Stief, C.G.4
-
35
-
-
0036883918
-
Sildernafil influences lower urinary tract symptoms
-
Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildernafil influences lower urinary tract symptoms. BJU Int 2002;90:836-839.
-
(2002)
BJU Int
, vol.90
, pp. 836-839
-
-
Sairam, K.1
Kulinskaya, E.2
McNicholas, T.A.3
Boustead, G.B.4
Hanbury, D.C.5
-
36
-
-
33745259309
-
Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction
-
Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006;3: 662-667.
-
(2006)
J Sex Med
, vol.3
, pp. 662-667
-
-
Mulhall, J.P.1
Guhring, P.2
Parker, M.3
Hopps, C.4
-
37
-
-
33846810223
-
Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind trial
-
McVary KT, Monning W, Camps JL, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007;177: 1071-1077.
-
(2007)
J Urol
, vol.177
, pp. 1071-1077
-
-
McVary, K.T.1
Monning, W.2
Camps, J.L.3
Young, J.M.4
Tseng, L.J.5
Van Den Ende, G.6
-
38
-
-
33947266450
-
Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia
-
McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177(4):1401-1407.
-
(2007)
J Urol
, vol.177
, Issue.4
, pp. 1401-1407
-
-
McVary, K.T.1
Roehrborn, C.G.2
Kaminetsky, J.C.3
-
39
-
-
50949119951
-
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A dose finding study
-
Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008;180(4):1228-1234.
-
(2008)
J Urol
, vol.180
, Issue.4
, pp. 1228-1234
-
-
Roehrborn, C.G.1
McVary, K.T.2
Elion-Mboussa, A.3
Viktrup, L.4
-
40
-
-
42749084255
-
A randomised, placebo-controlled study to assess the efficacy of twicedaily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia
-
Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twicedaily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53(6):1236-1244.
-
(2008)
Eur Urol
, vol.53
, Issue.6
, pp. 1236-1244
-
-
Stief, C.G.1
Porst, H.2
Neuser, D.3
Beneke, M.4
Ulbrich, E.5
-
41
-
-
80053308004
-
Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results of an international randomized, double-blind, placebocontrolled trial
-
Porst H, Kim ED, Casabe AR, et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebocontrolled trial. Eur Urol 2011;60(6):1105-1113.
-
(2011)
Eur Urol
, vol.60
, Issue.6
, pp. 1105-1113
-
-
Porst, H.1
Kim, E.D.2
Casabe, A.R.3
-
42
-
-
84855385961
-
Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: Results of a randomized, placebo-controlled, double-blind study
-
Egerdie RB, Auerbach S, Roehrborn CG, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 2012;9(1):271-281.
-
(2012)
J Sex Med
, vol.9
, Issue.1
, pp. 271-281
-
-
Egerdie, R.B.1
Auerbach, S.2
Roehrborn, C.G.3
-
43
-
-
84862777267
-
Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebocontrolled clinical trial
-
Oelke M, Guiliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebocontrolled clinical trial. Eur Urol. 2012;61:917-925.
-
(2012)
Eur Urol.
, vol.61
, pp. 917-925
-
-
Oelke, M.1
Guiliano, F.2
Mirone, V.3
Xu, L.4
Cox, D.5
Viktrup, L.6
-
44
-
-
34247360867
-
Combination of alfuzosin and sildenafil is superior to monotherapy in treating LUTS and ED
-
Kaplan S, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating LUTS and ED. Eur Urol 2007;51:1717-1723.
-
(2007)
Eur Urol
, vol.51
, pp. 1717-1723
-
-
Kaplan, S.1
Gonzalez, R.R.2
Te, A.E.3
-
45
-
-
51349092065
-
Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study
-
Bechara A, Romano S, Casabe A, Haime S, et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008;5:2170-2178.
-
(2008)
J Sex Med
, vol.5
, pp. 2170-2178
-
-
Bechara, A.1
Romano, S.2
Casabe, A.3
Haime, S.4
-
46
-
-
84861509305
-
Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms
-
Ozturk MI, Kalkan S, Koca O, Gunes M, AKyuz M, Karaman MI. Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms. Andrologia. 2012;44(S1):791-795.
-
(2012)
Andrologia.
, vol.44 S1
, pp. 791-795
-
-
Ozturk, M.I.1
Kalkan, S.2
Koca, O.3
Gunes, M.4
Akyuz, M.5
Karaman, M.I.6
-
47
-
-
79953216653
-
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A 1 year, open-label extension study
-
Donatucci CF, Brock GB, Goldfischer ER, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1 year, open-label extension study. BJU Int 2011;107:1110-1116.
-
(2011)
BJU Int
, vol.107
, pp. 1110-1116
-
-
Donatucci, C.F.1
Brock, G.B.2
Goldfischer, E.R.3
-
48
-
-
5444234921
-
Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men
-
Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004;172(5):1935-1940.
-
(2004)
J Urol
, vol.172
, Issue.5
, pp. 1935-1940
-
-
Kloner, R.A.1
Jackson, G.2
Emmick, J.T.3
-
49
-
-
34648830379
-
Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects
-
Guillaume M, Lonsdale F, Darstein C, Jimenez MC, Mitchell MI. Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects. J Clin Pharmacol 2007;47(10):1303-10.
-
(2007)
J Clin Pharmacol
, vol.47
, Issue.10
, pp. 1303-10
-
-
Guillaume, M.1
Lonsdale, F.2
Darstein, C.3
Jimenez, M.C.4
Mitchell, M.I.5
-
50
-
-
33744513290
-
Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects
-
Giuliano F, Kaplan SA, Cabanis MJ, Astruc B. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 2006;67(6):1199-1204.
-
(2006)
Urology
, vol.67
, Issue.6
, pp. 1199-1204
-
-
Giuliano, F.1
Kaplan, S.A.2
Cabanis, M.J.3
Astruc, B.4
-
51
-
-
77649339569
-
Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1aadrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men
-
MacDiarmid SA, Hill LA, Volinn W, Hoel G. Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1aadrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. Urology 2010;75 (3):520-525.
-
(2010)
Urology
, vol.75
, Issue.3
, pp. 520-525
-
-
MacDiarmid, S.A.1
Hill, L.A.2
Volinn, W.3
Hoel, G.4
-
52
-
-
19944427919
-
Effect of tadalafil on cytochrome P450 3A4-mediated clearance: Studies in vitro and in vivo
-
Ring BJ, Patterson BE, Mitchell MI, et al. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo. Clin Pharmacol Ther 2005;77(1):63-75.
-
(2005)
Clin Pharmacol Ther
, vol.77
, Issue.1
, pp. 63-75
-
-
Ring, B.J.1
Patterson, B.E.2
Mitchell, M.I.3
-
53
-
-
0346025675
-
Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients
-
Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:4-9.
-
(2004)
J Antimicrob Chemother
, vol.53
, pp. 4-9
-
-
Zeldin, R.K.1
Petruschke, R.A.2
-
54
-
-
0242552045
-
Time course of the interaction between tadalafil and nitrates
-
Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003;42(10):1855-1860.
-
(2003)
J Am Coll Cardiol
, vol.42
, Issue.10
, pp. 1855-1860
-
-
Kloner, R.A.1
Hutter, A.M.2
Emmick, J.T.3
Mitchell, M.I.4
Denne, J.5
Jackson, G.6
|